Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. - Wikidata - wikimedia - TriplyDB

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.

http://www.wikidata.org/entity/Q52880098

about

B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease Current perspectives on the immunopathogenesis of systemic sclerosis Therapeutic Approach to Adult Fibrotic Lung Diseases Management of Systemic-Sclerosis-Associated Interstitial Lung Disease Update on scleroderma-associated interstitial lung disease Targeted Therapy in Systemic Sclerosis Animal models of systemic sclerosis: their utility and limitations.Immunology of IgG4-related disease.Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon.[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.Mesenchymal stem cell therapy for refractory scleroderma: a report of 2 cases.Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections.Efficacy and safety of rituximab in rheumatic diseases.Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.Double heterozygous mice for Klf5 and Fli1 genes: a new animal model of systemic sclerosis recapitulating its three cardinal pathological features.Update on systemic sclerosis.The continuing evolution of targeted therapy for inflammatory skin disease.Recent advances in connective tissue disease related interstitial lung disease.Recent advances in animal models of systemic sclerosis.B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets.Strategy for treatment of fibrosis in systemic sclerosis: Present and future.Recent advances in managing systemic sclerosis.Interstitial lung disease in systemic sclerosis: current and future treatment.Management of connective tissue diseases associated interstitial lung disease: a review of the published literature.Current and future direction in the management of scleroderma.Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.Recent advances in the management of juvenile systemic sclerosis.Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment.Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.Extrahepatic Manifestations of Primary Biliary Cholangitis.Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity.New treatment directions for IPF: current status of ongoing and upcoming clinical trials.Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment.Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma.[Pulmonary fibrosis in rheumatic diseases].Scleroderma-related interstitial lung disease.Rituximab in early systemic sclerosis.

P2860

Q24658641-F0B1032E-C8FD-4700-A320-1E218C3D8655 Q26741264-FD739064-EE3D-4EB0-8AE7-22851BF1C2A1 Q26741569-77CB8D50-4F99-4ACD-9976-F084AFC6383C Q26799573-690B316D-9E78-44E7-A3CD-3ED231DF63F1 Q27016132-E3538E85-86A4-4090-A7F8-00DD00F7C398 Q28072943-BACE4EF4-18D1-49AA-B196-5D10E1B1CFA6 Q28390528-4816DF73-F5F7-4800-B715-406CE3A2427F Q34471314-4FFAED15-0C8A-4435-9C3A-5800966E4D0B Q34721223-D96D8653-7EA8-4053-936D-96D400C4A226 Q35257267-891CC04F-DAEE-4FAB-924D-E634307360EC Q36394613-6B409FFD-5514-47EF-BE81-B984E5B6E975 Q36975931-DF4E2F29-AEC7-483E-96A0-3D2BC03E7B24 Q37345076-2A8D3235-C87A-46CB-9F61-1A3B1F8E4252 Q37381549-D8618044-256C-4559-A4E7-BA777A0226E5 Q37690737-8DD5D540-68A6-4241-9540-F846A6173F8E Q38353577-F81C1E3C-91D5-4391-B1FF-E11F63193DC9 Q38379767-A9B2C7E2-AF9B-4BE6-9E57-423D96323A59 Q38489606-998340B3-F4D0-46D3-A603-64020AC6C1C7 Q38542317-11AEE313-2F37-4D5A-8EE1-E3E5A179F98E Q38596134-D1F54C91-2D69-4184-B0F4-62C62BF35CAC Q38678939-2752683D-EDCA-4332-BB4B-A276AAB8D670 Q38701983-BC145B10-74A2-43CE-8698-C7F8FF1C1B7F Q38701988-C4222007-F449-4B15-B35C-72200118A367 Q38701990-74415EC8-7D60-4D6F-8984-CFF468F40E5B Q38759138-7CFBB3B0-11C0-4BB0-927E-5CBAF25990DD Q38773637-F1D5F3C2-6492-4D82-8ED3-CF4F8BD3A3EE Q38793513-D3A76CB2-2192-40D2-9437-17FD2CBCA06E Q38823948-F8C7994A-BE74-4C50-8437-BF25129DABC3 Q38956376-083E642C-5ADF-4957-A43B-7D7400430F77 Q38969038-D6165320-3503-4BAA-9294-F3605F3F8805 Q38979780-8AF0F5C9-7651-49D9-829E-EA0C78BF4D73 Q39100810-07E79EB2-17AF-47CC-8B9B-78FCB0906545 Q39177903-99C2578F-61EE-403F-922D-32AF92DAA8E1 Q39272758-DA51BB92-FD9E-4859-9F56-5A4F996079D5 Q39330304-1F566B14-4591-430E-A4B8-F26AF3D43BCB Q39883870-27047064-A462-4961-B3DA-FF2A6B541498 Q40321155-B39189D1-B078-491D-BB4B-00E4F22BAFDB Q40543288-F42D6BD3-8265-4BF4-8AAF-EC960E4ABAFE Q41105228-BB331BDC-F583-41CD-AEB3-2199AC9E3992 Q41544232-45B7C60B-588C-4782-985A-A4C49589F01D

P2860

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.

http://www.wikidata.org/entity/Q52880098

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Effects and safety of rituxima ...... l and Research (EUSTAR) group.

@en

Effects and safety of rituxima ...... Scleroderma Trial and Research

@nl

type

label

Effects and safety of rituxima ...... l and Research (EUSTAR) group.

@en

Effects and safety of rituxima ...... Scleroderma Trial and Research

@nl

prefLabel

Effects and safety of rituxima ...... l and Research (EUSTAR) group.

@en

Effects and safety of rituxima ...... Scleroderma Trial and Research

@nl

P1433

Q52880098-06C01F26-97E6-4C02-BCEB-34869FA0A4CE

P1476

Q52880098-4CA1E03B-AEA7-42C9-9874-B303FA1D6EDA

P2093

Q52880098-471ECFF9-4281-40A8-B5B0-6A0514ADEF1D

Q52880098-4F78BC9C-AEBB-42A5-88CA-2EE8D60AC1FF

Q52880098-72DB2EDB-7934-463A-969E-1696434E0B7E

Q52880098-743E2168-E757-479F-8F4B-30930145573F

Q52880098-93E478A8-1ECD-4B9D-A933-770910F642B5

Q52880098-A17E6004-F90D-4C56-94AC-A04A89B21A53

Q52880098-A5B3A5B5-2D0F-43C7-8CCF-54068551EBD5

Q52880098-BF1D73A6-1052-401E-95A3-369F04B16E73

P2860

Q52880098-06381BD4-03DE-413F-9F3A-0760B7C16169

Q52880098-085E2622-D5E6-4E7B-A733-1ECDBD85CA5B

Q52880098-15179305-AEC6-4D90-9D79-510FD6128CFB

Q52880098-17876ADE-E51F-47AD-A851-2AC64C4F54C4

Q52880098-2C619E74-D377-4D48-BF92-B3ADABC86713

Q52880098-2CD2159D-C13C-4AC7-A720-EFE449D07262

Q52880098-3161B5D9-94D1-4C44-9718-70015ACE1FB8

Q52880098-3DBAF525-F61E-4367-9EFC-450A17F0F601

Q52880098-3F5EB765-7DDF-4292-80BD-465DF38847B2

Q52880098-59FB9287-1732-4968-AC7B-557C1DDE41CB

P304

Q52880098-25652906-7DA2-4822-9586-3CFCF7EF43D7

P31

Q52880098-C4C2C1B9-EF28-4359-B521-43084A85704F

P356

Q52880098-AE6B3F63-AAC6-4BB4-9533-D5837D9F91BE

P407

Q52880098-6138C4E2-3AAC-4501-917B-C72051802300

P433

Q52880098-CD653ECC-AA9D-4785-8AE1-0B0632B8C94C

P478

Q52880098-B1D80595-C72E-473F-8939-2B254362F430

P577

Q52880098-88AB1B74-6859-4E90-BF87-3EA223D08017

P5875

Q52880098-00E597A0-B268-4565-87F7-CDC527223C81

P698

Q52880098-B6F99FC8-F651-4F3F-91BB-010B1A678F7F

P356

ANNRHEUMDIS-2013-204522

P1433

Annals of the Rheumatic Diseases

P1476

Effects and safety of rituxima ...... l and Research (EUSTAR) group.

@en

P2093

Britta Maurer

http://www.w3.org/2001/XMLSchema#string

Dörte Huscher

http://www.w3.org/2001/XMLSchema#string

EUSTAR Rituximab study group

http://www.w3.org/2001/XMLSchema#string

Jacob M van Laar

http://www.w3.org/2001/XMLSchema#string

Jörg H W Distler

http://www.w3.org/2001/XMLSchema#string

Oliver Distler

http://www.w3.org/2001/XMLSchema#string

Suzana Jordan

http://www.w3.org/2001/XMLSchema#string

Yannick Allanore

http://www.w3.org/2001/XMLSchema#string

P2860

B cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.

B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.

B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

P304

1188-1194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2013-204522

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276482421

http://www.w3.org/2001/XMLSchema#string

P698

24442885

http://www.w3.org/2001/XMLSchema#string